Login / Signup

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

René-Olivier CasasnovasReda BouabdallahPauline BriceJulien LazaroviciHervé GhesquieresAspassia StamatoullasJehan DupuisAnne-Claire GacThomas GastinneBertrand JolyKrimo BouabdallahEmmanuelle Nicolas-VirelizierPierre FeugierJudith TrotmanDavid SibonChristophe BonnetAlina Berriolo-RiedingerVéronique EdelineMarie ParrensDiane DamotteDiane CosoMarc AndréMichel MeignanCédric Rossi
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The extended follow-up confirms the continued efficacy and favorable safety of AHL2011 PET-driven strategy, which is noninferior to standard six cycles of BEACOPP. PET4 provides additional prognostic information to PET2 and allows identifying patients with particularly poor prognosis.
Keyphrases
  • positron emission tomography
  • computed tomography
  • poor prognosis
  • pet ct
  • hodgkin lymphoma
  • phase iii
  • pet imaging
  • clinical trial
  • long non coding rna
  • open label
  • healthcare
  • social media
  • placebo controlled